Regorafenib and reactive metabolite of sunitinib activate inflammasomes: Implications for multi tyrosine kinase inhibitor-Iiduced immune related adverse eventsRyuji Kato, Yoshio Ijiri|Die Pharmazie|2022Cited by 4